Pharmalittle: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more
This morning in the Pharmalittle roundup: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more.
This morning in the Pharmalittle roundup: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more.
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew…
Zach Klaassen and Peter Goebell discuss a systematic review focused on treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Goebell’s study aims to assess if…
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, long-term illness that affects many body systems. People with ME/CFS are often not able to do their…
Sam Chang converses with Matthew Galsky about the ANTICIPATE II trial, examining the combination of APL-1202 (nitroxoline salt) and tislelizumab in treating muscle-invasive bladder cancer.…
Check out the latest edition of Adam’s Biotech Scorecard, a new newsletter from @statnews.
Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the integration of the Decipher Genomic Classifier tests across…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in…
U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, BIO says.
Michael Basin presents an analysis on FGFR alterations and the genomic landscape differences between upper and lower tract urothelial carcinoma. Utilizing data from the extensive…
These guidelines are designed to help clinicians incorporate the latest recommendations into their clinical practice.